Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2013 1
2015 2
2016 2
2017 3
2018 1
2019 2
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

13 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Predictive markers of safety and immunogenicity of adjuvanted vaccines.
Mastelic B, Garçon N, Del Giudice G, Golding H, Gruber M, Neels P, Fritzell B. Mastelic B, et al. Biologicals. 2013 Nov;41(6):458-68. doi: 10.1016/j.biologicals.2013.08.006. Epub 2013 Sep 23. Biologicals. 2013. PMID: 24071553
Vaccination represents one of the greatest public health triumphs; in part due to the effect of adjuvants that have been included in vaccine preparations to boost the immune responses through different mechanisms. ...Held at the U.S. Pharmacopeial Conv
Vaccination represents one of the greatest public health triumphs; in part due to the effect of adjuvants that have been inclu
Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.
Pavlick A, Blazquez AB, Meseck M, Lattanzi M, Ott PA, Marron TU, Holman RM, Mandeli J, Salazar AM, McClain CB, Gimenez G, Balan S, Gnjatic S, Sabado RL, Bhardwaj N. Pavlick A, et al. Cancer Immunol Res. 2020 Jan;8(1):70-80. doi: 10.1158/2326-6066.CIR-19-0545. Epub 2019 Nov 7. Cancer Immunol Res. 2020. PMID: 31699709 Free PMC article. Clinical Trial.
Despite promising results from early-phase clinical studies in patients with melanoma, NY-ESO-1 vaccine immunotherapy has not been widely investigated in larger trials; consequently, many questions remain as to the optimal vaccine formulation, predictive b
Despite promising results from early-phase clinical studies in patients with melanoma, NY-ESO-1 vaccine immunotherapy has not been wi …
Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial.
Salazar LG, Lu H, Reichow JL, Childs JS, Coveler AL, Higgins DM, Waisman J, Allison KH, Dang Y, Disis ML. Salazar LG, et al. JAMA Oncol. 2017 Jul 1;3(7):969-973. doi: 10.1001/jamaoncol.2016.6007. JAMA Oncol. 2017. PMID: 28114604 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate the safety and objective response rate (ORR) of imiquimod in combination with systemic albumin bound paclitaxel in treatment-refractory breast cancer of the chest wall. ...Preexisting levels of cells indicating either T-cell exhaustion or systemic im …
OBJECTIVE: To evaluate the safety and objective response rate (ORR) of imiquimod in combination with systemic albumin bound paclitaxe …
A library of recombinant Babesia microti cell surface and secreted proteins for diagnostics discovery and reverse vaccinology.
Elton CM, Rodriguez M, Ben Mamoun C, Lobo CA, Wright GJ. Elton CM, et al. Int J Parasitol. 2019 Feb;49(2):115-125. doi: 10.1016/j.ijpara.2018.10.003. Epub 2018 Oct 24. Int J Parasitol. 2019. PMID: 30367868 Free PMC article.
There is no licensed vaccine for B. microti and the development of a reliable serological screening test would contribute to ensuring the safety of the donated blood supply. ...Finally, we show that BmSA1 expressed in mammalian cells can elicit high antibody titres …
There is no licensed vaccine for B. microti and the development of a reliable serological screening test would contribute to ensuring …
A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.
Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, Hanjani P, Morgan M, Edwards R, Bradley W, Kolevska T, Foukas P, Swisher EM, Anderson KS, Gottardo R, Bryan JK, Newkirk M, Manjarrez KL, Mannel RS, Hershberg RM, Coukos G. Monk BJ, et al. Ann Oncol. 2017 May 1;28(5):996-1004. doi: 10.1093/annonc/mdx049. Ann Oncol. 2017. PMID: 28453702 Free PMC article. Clinical Trial.
BACKGROUND: A phase 2, randomized, placebo-controlled trial was conducted in women with recurrent epithelial ovarian carcinoma to evaluate the efficacy and safety of motolimod-a Toll-like receptor 8 (TLR8) agonist that stimulates robust innate immune responses-combined wit …
BACKGROUND: A phase 2, randomized, placebo-controlled trial was conducted in women with recurrent epithelial ovarian carcinoma to evaluate t …
Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).
Saiag P, Gutzmer R, Ascierto PA, Maio M, Grob JJ, Murawa P, Dreno B, Ross M, Weber J, Hauschild A, Rutkowski P, Testori A, Levchenko E, Enk A, Misery L, Vanden Abeele C, Vojtek I, Peeters O, Brichard VG, Therasse P. Saiag P, et al. Ann Oncol. 2016 Oct;27(10):1947-53. doi: 10.1093/annonc/mdw291. Epub 2016 Aug 8. Ann Oncol. 2016. PMID: 27502712 Free PMC article. Clinical Trial.
The MAGE-A3 immunotherapeutic was similarly immunogenic in both populations and had a clinically acceptable safety profile. CONCLUSION: Treatment of patients with MAGE-A3-positive unresectable stage IIIB-C/IV-M1a melanoma with the MAGE-A3 immunotherapeutic demonstra …
The MAGE-A3 immunotherapeutic was similarly immunogenic in both populations and had a clinically acceptable safety profile. CO …
Beyond CTLA-4: novel immunotherapy strategies for metastatic melanoma.
Matikas A, Mavroudis D. Matikas A, et al. Future Oncol. 2015;11(6):997-1009. doi: 10.2217/fon.14.287. Future Oncol. 2015. PMID: 25760979 Review.
However, the potential adverse events, the optimal use of these modalities, the high cost and the absence of predictive markers remain unmet challenges. Herein, we review the immunotherapy strategies in melanoma, either approved or under evaluation, and present the …
However, the potential adverse events, the optimal use of these modalities, the high cost and the absence of predictive markers
A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial.
Nakajima M, Hazama S, Tamada K, Udaka K, Kouki Y, Uematsu T, Arima H, Saito A, Doi S, Matsui H, Shindo Y, Matsukuma S, Kanekiyo S, Tokumitsu Y, Tomochika S, Iida M, Yoshida S, Nakagami Y, Suzuki N, Takeda S, Yamamoto S, Yoshino S, Ueno T, Nagano H. Nakajima M, et al. Cancer Immunol Immunother. 2020 Aug;69(8):1651-1662. doi: 10.1007/s00262-020-02518-7. Epub 2020 Mar 26. Cancer Immunol Immunother. 2020. PMID: 32219501 Free PMC article. Clinical Trial.
BACKGROUND: This phase I study aimed to evaluate the safety, peptide-specific immune responses, and anti-tumor effects of a novel vaccination therapy comprising multi-HLA-binding heat shock protein (HSP) 70/glypican-3 (GPC3) peptides and a novel adjuvant comb …
BACKGROUND: This phase I study aimed to evaluate the safety, peptide-specific immune responses, and anti-tumor effects of a novel …
Immunotherapies in Early and Advanced Renal Cell Cancer.
Kasenda B, Larkin J, Gore M. Kasenda B, et al. Prog Tumor Res. 2015;42:1-10. doi: 10.1159/000436988. Epub 2015 Sep 4. Prog Tumor Res. 2015. PMID: 26376844 Review.
Vaccines have continued to be investigated in advanced and adjuvant settings. No trial has so far established vaccines as a standard treatment in either situation. ...We will also touch briefly on the adjuvant situation and tumour vaccines....
Vaccines have continued to be investigated in advanced and adjuvant settings. No trial has so far established vaccines
Clinical trials with allergen products: in search of biological markers of efficacy.
Moingeon P. Moingeon P. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 2006;(95):182-7; discussion 187-8. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 2006. PMID: 17393738
I discuss herein our efforts to identify biological markers of efficacy in support of the development of sublingual allergy vaccines. Biomarkers are of major interest to facilitate clinical development, for example by predicting safety and effic …
I discuss herein our efforts to identify biological markers of efficacy in support of the development of sublingual allergy vaccin
13 results
Jump to page
Feedback